ArticleBriefings in bioinformatics2025
A free energy perturbation-assisted machine learning strategy for mimotope screening in neoantigen-based vaccine design.
Article in Briefings in bioinformatics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- PMGen: from peptide-MHC structure prediction to peptide generation.Bioinformatics (Oxford, England) · 2026Article
- Targeted biologics for TNBC: Advances in nanobodies, antibodies, peptides, and aptamers.Molecular therapy. Oncology · 2026Review
- EpiMII: Structure-Aware Graph Neural Networks for MHC-II Epitope Generation.Research (Washington, D.C.) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Neoantigen-based immunotherapy has emerged as a promising approach for cancer treatment. One key strategy in neoantigen-based vaccine design is to alter known neoantigens into enhanced mimotopes that elicit more robust immune responses. However, screening mimotopes presents challenges in both diversity and precision. While machine learning (ML) models facilitate high-throughput screening of immunogenic candidates, they struggle to distinguish mimotopes from original neoantigens (i.e. identify mimotopes with higher binding affinities, rather than solely distinguish between binding and nonbinding peptides). In contrast, alchemical methods such as free energy perturbation (FEP) provide quantitative binding free-energy differences between mimotopes and neoantigens but are computationally intensive. To leverage the strengths of both approaches, we propose an FEP-assisted ML (FEPaML) strategy that employs Bayesian optimization to iteratively refine knowledge-based predictions with physics-based evaluations, thereby progressively achieving locally optimized, precise, and robust outcomes. Our FEPaML strategy is then applied to screen mimotopes for several representative neoantigens. It has demonstrated excellent predictive precisions (exceeding 0.9) with a relatively small number of FEP samplings, significantly outperforming existing ML models.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.